In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions.  We’re pleased to share several notable developments

We have continued to successfully manage our business despite the challenges in our operating environment. Our team has remained dedicated to delivering high-quality medicines for our patients, while also developing new medicines for the future.  We’re pleased to share several notable developments from the first quarter of 2023:   The FDA